drugset / Trial / NCT00842400
A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.
Non-randomizedCrossoverOpen-label
Summary
The purposes of this study are to: * Find out how much of the study drugs are in the blood of healthy subjects after taking multiple doses of VI-0521, metformin and sitagliptan. * Determine the effect of probenecid on the amount of VI-0521 in the blood of healthy subjects after taking multiple doses. * Find out how much topiramate is in the semen of healthy male subjects after taking multiple doses.
Timeline
- Start
- 2009-02
- Primary completion
- 2009-03
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | Oral |
| Subject | Phentermine | Small molecule | 3.75 mg | Oral |
| Subject | Phentermine | Small molecule | 7.5 mg | Oral |
| Subject | Phentermine | Small molecule | 11.25 mg | Oral |
| Subject | Phentermine | Small molecule | 15 mg | Oral |
| Subject | Probenecid | Small molecule | 2 g | Oral |
| Subject | Sitagliptan | Unknown | 100 mg | Oral |
| Subject | Topiramate | Small molecule | 23 mg | Oral |
| Subject | Topiramate | Small molecule | 46 mg | Oral |
| Subject | Topiramate | Small molecule | 69 mg | Oral |
| Subject | Topiramate | Small molecule | 92 mg | Oral |